Why NRx Pharmaceuticals, Inc.’s (NRXP) Stock Is Down 6.81%
As of Wednesday, August 26, NRx Pharmaceuticals, Inc.’s NRXP share price has dipped by 6.81%, which has investors questioning if this is right time to buy.Rosalio Madrigal
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
NRx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder (PTSD), and schizophrenia in the United States. It operates through NRx and Dura segments. The company develops NRX-101, an oral fixed-dose combination of D-cycloserine (DCS) and lurasidone in Phase 2/3 clinical testing for bipolar depression with sub-acute ideation and behavior; NRX-100, a preservative-free formulation of ketamine for intravenous infusion and for the treatment of suicidal depression; and KETAFREE, a generic preservative-free formulation of ketamine. It also provides precision-based interventional psychiatry services to patients with treatment-resistant depression and PTSD using a combination of neuroplastic drugs, transcranial magnetic stimulation (TMS), digital therapeutics, and hyperbaric therapy; ketamine infusion therapy; stellate ganglion blocks; Spravato administration; psychotherapy; and medication management. The company has a development and license agreement with Glytech LLC. NRx Pharmaceuticals, Inc. was founded in 2015 and is headquartered in Wilmington, Delaware.
Commentary & Analysis
Why NRx Pharmaceuticals, Inc.’s (NRXP) Stock Is Up 5.22%
As of Tuesday, August 25, NRx Pharmaceuticals, Inc.’s NRXP share price has surged by 5.22%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why NRx Pharmaceuticals, Inc.’s (NRXP) Stock Is Up 5.50%
As of Monday, August 17, NRx Pharmaceuticals, Inc.’s NRXP share price has surged by 5.50%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Why NRx Pharmaceuticals, Inc.’s (NRXP) Stock Is Up 7.44%
As of Thursday, August 13, NRx Pharmaceuticals, Inc.’s NRXP share price has surged by 7.44%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Why NRx Pharmaceuticals, Inc.’s (NRXP) Stock Is Up 5.07%
As of Tuesday, August 11, NRx Pharmaceuticals, Inc.’s NRXP share price has surged by 5.07%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Financial Summary
| Share Statistics | NRXP | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $149.5 | $674.0 | 25% |
|
| Shares Out (Mil) | 37.6 | 43.9 | 41% |
|
| Institutional Ownership | 83.9% | 84.7% | 52% |
|
| Float (Mil) | 36.4 | 47.3 | 40% |
|
| Beta | 2.18 | 0.71 | 94% |
|
| Avg Daily Volume (000s) | 674 | 293 | 65% |
|
| Price Change (52-week) |
32.9% | 68.8% | 72% |
|
| Growth | NRXP | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 6.8% | na |
|
| Net Income (5yr) | 11.2% | (1.5%) | 57% |
|
| EPS (5yr) | 38.4% | 14.9% | 88 |
|
| Dividends (5yr) | na | 0.0% | 0% |
|
| Cash Flow (5yr) | 0.7% | (15.1%) | 65% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 1 | 1 | 1 | |
| Current EPS | ($0.080) | ($0.360) | $0.500 | |
| Month Ago EPS | ($0.080) | ($0.360) | $0.500 | |
| # Rev Up | 0 | 0 | 1 | |
| # Rev Down | 1 | 1 | 0 | |
| Three Months Ago EPS | ($0.080) | ($0.360) | $0.500 | |
| Year/Year Chg | (81.8%) | (73.1%) | (111.2%) | |
| Financials | NRXP | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $3 | $317 | 4% |
|
| Net Income (TTM) (Mil) | ($24) | ($11) | 22% |
|
| EPS (TTM) | ($0.775) | ($0.700) | 24% |
|
| Operating Cash Flow (TTM) (Mil) | ($20) | ($7) | 15% |
|
| Net Cash Flow (TTM) (Mil) | $24 | $4 | 63% |
|
| Long-Term Debt (Q1) (Mil) | $1 | $6 | 15% |
|
| Enterprise Value (Q1) (Mil) | $123 | $575 | 22% |
|
| Valuation | NRXP | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 2.80 | na |
|
| P/E | na | 17.4 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | NRXP | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 46.6% | 67.5% | 58% |
|
| Net Margin | (691.8%) | (1.4%) | 1% |
|
| ROA | (120.4%) | (24.6%) | 5% |
|
| ROE | 131.2% | (21.4%) | 97% |
|
| Liabilities to Assets | 100.5% | 32.2% | 94% |
|
| F-Score | 3 | 3 | 18% |
|
NRx Pharmaceuticals, Inc. did not pass any screens on 9/2/2026.
